- What is Neurogenic's primary focus?
- Neurogenic is a clinical-stage diagnostics company that develops sensitive immunoassays to aid in the diagnosis of mental disorders.
- What specific condition is Neurogenic's current assay designed to detect?
- Neurogenic's current assay is an ELISA-based immunoassay designed to detect autoimmune Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients with early-onset symptoms of schizophrenia.
- What is the current development stage of Neurogenic's assay?
- Neurogenic is in the final stages of assay optimization and is continuing clinical field testing and validation of the assay.
- With which institutions has Neurogenic established collaborations?
- Neurogenic has long-term collaborations with the Weizmann Institute of Science, Tel Aviv University's Department of Psychiatry, Beer Yaakov-Ness-Ziona Mental Health Center, Geha Mental Health Center, and the Laboratory of Biological Psychiatry at Felsenstein Medical Research Center.
- When was Neurogenic founded?
- Neurogenic was founded in February 1995.
- How many employees does Neurogenic have?
- Neurogenic has 1-10 employees.
- What is Neurogenic's current funding stage?
- Neurogenic is currently in the Pre-Funding stage.
- In which sector does Neurogenic primarily operate?
- Neurogenic's primary sector is Health Tech & Life Sciences.